NDA 216023 · Blue Earth
Posluma
Flotufolastat F-18 Gallium · Intravenous · Radioactive Diagnostic Agent
NovelCDER novel approval, May 25, 2023: To use with positron emission tomography imaging in certain patients with prostate cancer
Last checked: Nov 20, 2026Latest source record: Jan 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 25, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
0 Phase 3, 3 recruiting
FAERS reports
49
6 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 25, 2026.
POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. POSLUMA is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. ( 1 )
Mechanism: Flotufolastat F 18 binds to PSMA (IC50 = 4.4 nM) expressed on cells, including prostate cancer cells, and is internalized. Prostate cancer cells usually overexpress PSMA. Fluorine-18 is a ß+ emitting radionuclide that can be detected using positron emission tomography.
Therapeutic areas: Oncology · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- POSLUMA · FLOTUFOLASTAT F-18 GALLIUM 25ML (8-158mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Flotufolastat F-18 Gallium" as an intervention, any sponsor and status, largest first.
Emory UniversityAcademic, hospital or other
NCT06865768 · 90 participants (planned) · Start Apr 18, 2025 · Primary completion Dec 31, 2028
Drug: Flotufolastat F-18 Gallium · For: Prostate Carcinoma
Sites: Atlanta, Georgia
Mayo ClinicAcademic, hospital or other
NCT07025369 · 30 participants (planned) · Start Aug 25, 2025 · Primary completion Jan 1, 2029
Drug: Relugolix · For: Prostate Adenocarcinoma; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8 and 1 more
Sites: Scottsdale, Arizona
Northwestern UniversityAcademic, hospital or other
NCT06813898 · 27 participants (planned) · Start Apr 11, 2025 · Primary completion Feb 1, 2027
Drug: Flotufolastat F-18 Gallium · For: Biochemically Recurrent Prostate Carcinoma; Prostate Adenocarcinoma
Sites: Chicago, Illinois
Novartis PharmaceuticalsNovartis (NVS)
NCT06881823 · 0 participants · Start Jun 29, 2026 · Primary completion Mar 31, 2030
Drug: AAA602; AAA802 and 4 more · For: Prostate Cancer
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- positron emission tomogram abnormal14
- no adverse event9
- drug effect less than expected8
- hot flush4
- incorrect dose administered4
- overdose4
- wrong product administered3
- covid-192
- dizziness2
- drug ineffective2
- product dispensing error2
- underdose2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 13 |
| 2025 | 21 |
| 2026 | 15 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Blue Earth
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.